[HTML][HTML] Skeletal muscle mass is an imaging biomarker for decreased survival in patients with oropharyngeal squamous cell carcinoma
N Chargi, SI Bril, JE Swartz, I Wegner, SM Willems… - Oral oncology, 2020 - Elsevier
Objectives Low skeletal muscle mass (SMM) and sarcopenic obesity (co-presence of low
SMM and obesity) are emerging prognosticators in oncology, but the prevalence and …
SMM and obesity) are emerging prognosticators in oncology, but the prevalence and …
Skeletal muscle mass is an imaging biomarker for decreased survival in patients with oropharyngeal squamous cell carcinoma
N Chargi, SI Bril, JE Swartz, I Wegner, SM Willems… - Oral …, 2020 - research.rug.nl
Objectives: Low skeletal muscle mass (SMM) and sarcopenic obesity (co-presence of low
SMM and obesity) are emerging prognosticators in oncology, but the prevalence and …
SMM and obesity) are emerging prognosticators in oncology, but the prevalence and …
Skeletal muscle mass is an imaging biomarker for decreased survival in patients with oropharyngeal squamous cell carcinoma.
N Chargi, SI Bril, JE Swartz, I Wegner, SM Willems… - Oral …, 2019 - europepmc.org
Objectives Low skeletal muscle mass (SMM) and sarcopenic obesity (co-presence of low
SMM and obesity) are emerging prognosticators in oncology, but the prevalence and …
SMM and obesity) are emerging prognosticators in oncology, but the prevalence and …
Skeletal muscle mass is an imaging biomarker for decreased survival in patients with oropharyngeal squamous cell carcinoma
N Chargi, SI Bril, JE Swartz, I Wegner… - Oral …, 2020 - pubmed.ncbi.nlm.nih.gov
Objectives Low skeletal muscle mass (SMM) and sarcopenic obesity (co-presence of low
SMM and obesity) are emerging prognosticators in oncology, but the prevalence and …
SMM and obesity) are emerging prognosticators in oncology, but the prevalence and …